Friday, March 07, 2025 1:27:42 PM
Well said... Anavex remains a positive investment. but as history shows us, this equity gets traded and shorted in a wall street game that takes trading skills to play along with. Years of patience, and professional emotions, staying calm when the short attacks send the price down, while good news isn't appreciated enough by the market. And while we watch the other big pharma drugs get approved but they fail to help patients, you can see the corruption of the medical system. Does anyone trust the FDA to demonstrate honest integrity? In any case, if AVXL is best seen as a combination of a core investment to hold, alongside a trading portion to trade, my job is to buy low and sell high with the trades. Looking for targets in the chart currently, we see resistance at 8.60-9.00 area. We're seeing whipsaw, pop and drop patterns... clever manipulation climbing price, today's a perfect example... price climbs higher , tumbles at resistance, and then falls to Lower lows. Lower lows, opens the door to more lower lows. Where are the lower targets holding support. Right now, it's 8.30 to 8 dollars. And previous support lows are 7.90 and 7.70. Below that is 7.50 to 7.16. Bottom target zones can bounce at the same area several times. Right now it's been around 8 dollars, but bleeds thru to 7.90, maybe next month we'd see that bouncing happen around 7.70/7.60.... it's all a trading game seeking lower lows and lowest bottoms. To Buy. And the tricky game is how the price movements make you think support will hold at certain bullish pullback targets like (currently it was 8.50) but look at the plunge down today to 8.37..... lower low. And that changes the pattern, weakens the bullish movement, and strengthens the bearish bias. In a neutral viewpoint, we saw a rally from 7.70/7.90 to 8.90... and the pullback is tumbling back down like it wants to retest 8.00 again. At best, this is a Range pattern, not a rally upwave pattern. Upwave pattern should've held around 8.50. Now, 8.60 is resistance. and looking downward in my view. This 8.60 resistance has been in play for a month, waiting to roll over, and it finishes the week poised to roll over and tumble back to 8 dollars. And maybe into the 7's.
As you know, the patterns are all about support/resistance targets and pivots making higher highs/higher lows going up, or lower highs and lower lows going down. Today's low is a lower low in the short term pattern. How low will this pattern go, is the bleeding down trading game. There's target at 8.30/8.15/8.00/7.90/7.70. If we see strong support with volume holding around 8.30, we might still have a bullish bias. But in older chart patterns, as the 100 ma shows... the bullish support wants to see higher price holding stronger, above 8.50, closer to 9.00 and regaining that zone Citrati shows, get going higher, break through 9.00 and 9.30, retest the upper Bollinger at 9.75, retest 9.80 resistance, test 10 dollars.... that's a bullish looking recovery wave. Stop bleeding downward. 8 dollars is important to hold strong.
As you know, the patterns are all about support/resistance targets and pivots making higher highs/higher lows going up, or lower highs and lower lows going down. Today's low is a lower low in the short term pattern. How low will this pattern go, is the bleeding down trading game. There's target at 8.30/8.15/8.00/7.90/7.70. If we see strong support with volume holding around 8.30, we might still have a bullish bias. But in older chart patterns, as the 100 ma shows... the bullish support wants to see higher price holding stronger, above 8.50, closer to 9.00 and regaining that zone Citrati shows, get going higher, break through 9.00 and 9.30, retest the upper Bollinger at 9.75, retest 9.80 resistance, test 10 dollars.... that's a bullish looking recovery wave. Stop bleeding downward. 8 dollars is important to hold strong.
Recent AVXL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
